Skip to content
OpenCapital
Get started

BridgeBio Pharma BBIO Reportable Segment — Restructuring, impairment, and related charges

Similar metrics at other companies

Baxter International logo
BAXReportable Segment — Business optimization items
-$44.5M-9.9%
Planet Labs logo
PLReportable Segment — Restructuring Charges
$0-100%
Incyte logo
INCYReportable Segment — Asset impairment and related disposal costs
$23.21M—
Planet Labs logo
PLReportable Segment — Restructuring costs
$2.64M+43.4%
Akamai Technologies logo
AKAMReportable Segment — Restructuring charge
$183K-49.3%
US Foods logo
USFDReportable Segment — Restructuring activity and asset impairment charges
$8M+60.0%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:RestructuringSettlementAndImpairmentProvisions.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's reportable segment — restructuring, impairment, and related charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's reportable segment — restructuring, impairment, and related charges?
BridgeBio Pharma (BBIO) reported reportable segment — restructuring, impairment, and related charges of $0 in Q1 2026.
How has BridgeBio Pharma's reportable segment — restructuring, impairment, and related charges changed year-over-year?
BridgeBio Pharma's reportable segment — restructuring, impairment, and related charges decreased by 100.0% year-over-year, from $570K to $0.
What does reportable segment — restructuring, impairment, and related charges mean?
One-time costs related to restructuring or asset value write-downs.
How do you interpret reportable segment — restructuring, impairment, and related charges?
High or frequent charges suggest operational instability or poor historical capital allocation.
How does reportable segment — restructuring, impairment, and related charges compare across companies?
Standard non-recurring charge reporting for public companies.